Tixagevimab Cilgavimab — Competitive Intelligence Brief

Tixagevimab Cilgavimab (Tixagevimab Cilgavimab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Infectious disease.

phase 3 Monoclonal antibody SARS-CoV-2 spike protein Infectious disease Small molecule

Target snapshot

Tixagevimab Cilgavimab (Tixagevimab Cilgavimab) — Azienda Ospedaliera Universitaria Integrata Verona. Tixagevimab and cilgavimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein, preventing viral entry into host cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tixagevimab Cilgavimab TARGET	Tixagevimab Cilgavimab	Azienda Ospedaliera Universitaria Integrata Verona	phase 3	Monoclonal antibody	SARS-CoV-2 spike protein
mRNA-1273 vaccine	mRNA-1273 vaccine	University Health Network, Toronto	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Intramuscularly administered Ad5-nCoV vaccine	Intramuscularly administered Ad5-nCoV vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
Lilly Bamlanivimab + Etesevimab	Lilly Bamlanivimab + Etesevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
Comirnaty Original/Omicron BA.1	Comirnaty Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
Regeneron Casirivimab + Imdevimab	Regeneron Casirivimab + Imdevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein
Pfizer-COVID-19 Vaccine	Pfizer-COVID-19 Vaccine	National Heart, Lung, and Blood Institute (NHLBI)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

1. Pfizer · 7 drugs in this class
2. argenx · 7 drugs in this class
3. Johnson & Johnson · 2 drugs in this class
4. German CLL Study Group · 2 drugs in this class
5. Amgen · 2 drugs in this class
6. Hoffmann-La Roche · 2 drugs in this class
7. Brii Biosciences Limited · 2 drugs in this class
8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
9. Biotest · 2 drugs in this class
10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class